99mTc-labeled single-domain antibody EG2 in targeting epidermal growth factor receptor: an in-vitro and mouse model in-vivo study

  title={99mTc-labeled single-domain antibody EG2 in targeting epidermal growth factor receptor: an in-vitro and mouse model in-vivo study},
  author={Chongjiao Li and Bing Wen and Lifei Wang and Hongyan Feng and Xiaotian Xia and Zhi-qiang Ding and Bin Gao and Yongxue Zhang and Xiaoli Lan},
  journal={Nuclear Medicine Communications},
ObjectiveThe aim of this study was to explore the targeting ability and metabolic characteristics of the technetium-99m-labeled single-domain antibody (99mTc-sdAb) EG2 targeting epidermal growth factor receptor (EGFR) through an in-vitro and in-vivo study. Materials and methodsThe sdAb EG2 was radiolabeled with 99mTc using a tricarbonyl kit. The EGFR expression level of A431 and OCM-1 cells was confirmed using immunofluorescence staining. Cell binding, blocking, uptake, and efflux studies were… Expand
(99m) Tc-labeled tetramer and pentamer of single-domain antibody for targeting epidermal growth factor receptor in xenografted tumors.
EG2-COMP shows promise in identifying EGFR over-expression in tumors; however, EG2-RHCC may not be suitable for targeting EGFR in vivo. Expand
Radioimmunoimaging of 125 I ‐ labeled anti ‐ CD 93 monoclonal antibodies in a xenograft model of non ‐ small cell lung cancer
Lung cancer, especially non-small cell lung cancer (NSCLC), is the most common malignant tumor associated with poor prognosis. Angiogenesis plays a vital role in NSCLC, and could be used in tumorExpand
EGFR and anti-EGFR nanobodies: review and update
The structure and function of EGFR and Nb, the current status of EG FR targeting, and recent developments in anti-EGFR Nbs are discussed. Expand
Synthesis, Characterization, and Initial Biological Evaluation of [99mTc]Tc‐Tricarbonyl‐labeled DPA‐α‐MSH Peptide Derivatives for Potential Melanoma Imaging
Preliminary in vivo studies with one of the [99mTc]Tc‐tricarbonyl–peptide conjugates showed good stability in blood and both renal and hepatobiliary excretion, and negligible trans‐chelation and high stability in physiological solutions was determined. Expand
Radiolabeled nanobodies for tumor targeting: From bioengineering to imaging and therapy.
Nbs characteristics, the diagnostic and therapeutic application of their radioconjugates, and their recent advances are described, which assumes that they may overcome generic problems of monoclonal antibodies, their fragments, and other vectors for tumor imaging/therapy. Expand


PET imaging of CD105/endoglin expression with a 61/64Cu-labeled Fab antibody fragment
  • Yin Zhang, H. Hong, +5 authors W. Cai
  • Chemistry, Medicine
  • European Journal of Nuclear Medicine and Molecular Imaging
  • 2012
PET imaging of CD105 expression using 61/64Cu-NOTA-TRC105-Fab, which exhibited prominent and target-specific uptake in the 4T1 tumor, is reported. Expand
Localization, mechanism and reduction of renal retention of technetium-99m labeled epidermal growth factor receptor-specific nanobody in mice.
Megalin contributes to the renal accumulation of (99m)Tc-7C12 and the combined effect of gelofusine and lysine was the most effective, namely a reduction of renal retention and improved tumor uptake. Expand
Molecular Design and Optimization of 99mTc-Labeled Recombinant Affibody Molecules Improves Their Biodistribution and Imaging Properties
99mTc-ZHER2:V2 is a promising candidate for further development as a diagnostic radiopharmaceutical for imaging of HER2-expressing tumors and may be useful for the development of imaging agents based on other Affibody molecules and, hopefully, other scaffolds. Expand
SPECT Imaging with 99mTc-Labeled EGFR-Specific Nanobody for In Vivo Monitoring of EGFR Expression
The EGFR-binding Nanobody investigated in this study shows high specificity and selectivity towards EGFR overexpressing cells, which corroborates the suitability of Nanobodies for in vivo tumor imaging. Expand
Comparison of the Biodistribution and Tumor Targeting of Two 99mTc-Labeled Anti-EGFR Nanobodies in Mice, Using Pinhole SPECT/Micro-CT
The Nanobody fragments used here show high tumor uptake, low liver uptake, and rapid blood clearance, and Nanobodies are promising probes for noninvasive radioimmunodetection of specific targets early after administration. Expand
Synthesis, Preclinical Validation, Dosimetry, and Toxicity of 68Ga-NOTA-Anti-HER2 Nanobodies for iPET Imaging of HER2 Receptor Expression in Cancer
A new anti-HER2 PET tracer, 68Ga-NOTA-2Rs15d, was synthesized via a rapid procedure under mild conditions and showed high-specific-contrast imaging of HER2-positive tumors with no observed toxicity. Expand
Correlating EGFR Expression with Receptor-Binding Properties and Internalization of 64Cu-DOTA-Cetuximab in 5 Cervical Cancer Cell Lines
64Cu-DOTA-cetuximab was successfully used to detect and quantify EGFR expression in cervical cancer tumors, and small-animal PET/ CT of EGFR-expressing CaSki tumors suggests potential for PET/CT of EG FR-positive tumors. Expand
Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-ZEGFR:2377 Affibody molecule: aspect of the injected tracer amount
The 111In-DOTA-ZEGFR:2377 Affibody molecule is a promising tracer for radionuclide molecular imaging of EGFR expression in malignant tumours but careful optimization of protein dose is required for high-contrast Imaging of EG FR expression in vivo. Expand
Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors.
64Cu-DOTA-cetuximab is a potential agent for imaging EGFR-positive tumors in humans and was relatively stable in the blood of tumor-bearing mice; however, there was significant metabolism in the liver and tumors. Expand
Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody
The success of EGFR-positive tumor imaging using 64Cu-DOTA-cetuximab can be translated into the clinic to characterize the pharmacokinetics, to select the right population of patients for EGFR -targeted therapy, and to monitor the therapeutic efficacy of anti-EGFR treatment. Expand